Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

University of California, Los Angeles (UCLA)

Status: Unknown

Conditions: Analgesic Response

Treatments: Drug: oral tablet placebo; Drug: morphine sulfate; Drug: hydromorphone HCI; Drug: oxycodone; Drug: buprenorphine; Drug: sublingual tablet placebo; Drug: hydrocodone

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02136784

13-001175

Details and patient eligibility

About

The aim of this study is to examine the effects of opioid analgesics on acute pain in participants maintained on buprenorphine+naloxone (Suboxone) for opioid use disorders. Seven medication conditions will be tested in a cold pressor test (CPT) paradigm.

Full description

Study design is a single-blind examination of the analgesic effects of a single dose of seven test medications provided in an experimental pain paradigm using a cold pressor test (CPT). Test medication conditions include buprenorphine, morphine, hydromorphone, hydrocodone, oxycodone, and two placebo conditions to match test medication formulations (oral tablet, sublingual tablet). Each medication condition will be tested on separate days (seven total days, completing within 12 weeks), with random assignment to order of study medications. After screening, eligible participants will be scheduled for 7 days of testing with test days at least 3 days apart to provide a sufficient medication wash-out period. Pain testing will utilize cold pressor tests (CPT), in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance. Participants will be given a practice trial to provide familiarity with the test and reduce test anxiety. Two CPTs will occur on each test day, and pre- and post-CPT assessments will be administered. Blood samples will be taken on each test day to measure blood levels of buprenorphine. Daily procedures include: (1) A baseline CPT (BL-CPT), (2) Administration of the test medication (active drug or placebo), (3) CPT administered at the time of maximum drug effect (Tmax-CPT) specific to medication (range 30-120 minutes), (4) Pupillometry conducted at baseline (before BL-CPT), and at time of maximum drug effect (before Tmax-CPT). Each participant will be discharged after clinical determination of the participant's safety and well-being. Testing will continue until twelve trials of each medication condition are completed.

Enrollment: 12 estimated patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male, in good general health
2. 20-50 years old
3. Fluent in English
4. Maintained on buprenorphine for at least 3 months
5. Able to complete testing/assessments for 7 test days within 12 weeks
6. Approved for participation by buprenorphine-prescribing physician

Exclusion criteria

1. Known hypersensitivity to any of the test opioids
2. Urine test positive for opioids (other than buprenorphine) or other illicit substances
3. Current use of any additional opioid or analgesic medication (other than buprenorphine), medical marijuana, MAOI, tricyclic antidepressant, duloxetine, gabapentin, pregabalin, or other medication considered unsafe or having potential to influence pain perception as determined by study physician.
4. Presence of acute pain condition or planned surgery during the study period
5. Unstable vital signs as determined by the study physician.
6. Current pattern of alcohol, benzodiazepine, or other sedative hypnotic use, as determined by the study medical clinician, which would preclude safe participation in the study;
7. Pending legal action or other situation that might prevent remaining in the area for the duration of the study
8. Current medical or psychiatric condition that could detract from study objectives, place the participant at risk, or interfere with treatment goals

Trial design

12 participants in 7 patient groups, including a placebo group

morphine sulfate

Experimental group

Description:

30mg, single dose,

Treatment:

Drug: oral tablet placebo

hydrocodone

Experimental group

Description:

10mg single dose

Treatment:

Drug: oral tablet placebo

hydromorphone HCI

Experimental group

Description:

4mg single dose

Treatment:

Drug: oral tablet placebo

oxycodone

Experimental group

Description:

10 mg single dose

Treatment:

Drug: oral tablet placebo

buprenorphine

Experimental group

Description:

4 mg single dose

Treatment:

Drug: sublingual tablet placebo

oral tablet placebo

Placebo Comparator group

Description:

single dose

Treatment:

Drug: hydrocodone

Drug: oxycodone

Drug: hydromorphone HCI

Drug: morphine sulfate

sublingual tablet placebo

Placebo Comparator group

Description:

single dose

Treatment:

Drug: buprenorphine